New products contributed £377 million to total sales at GlaxoSmithKline in the 2009 second quarter, up by 42% from the first quarter. Included in this category were two vaccines, Rotarix for gastro-enteritis, and Cervarix for cervical cancer, which produced combined sales of £144 million.
